Related Experiment Videos
Association between CYP2E1 polymorphisms and susceptibility to prostate cancer
P M Ferreira1, R Medeiros, A Vasconcelos
1Molecular Oncology Unit, Instituto Português de Oncologia do Porto, Portugal. paulamsferreira@mail.com
Summary
Genetic variations in CYP2E1, specifically DraI polymorphisms, are linked to prostate cancer (PCa) risk. The DD genotype of DraI may double the risk of developing PCa.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Background:
- Sporadic prostate cancer (PCa) is linked to various genetic alterations.
- The CYP2E1 gene is a potential candidate for investigating PCa susceptibility.
Purpose of the Study:
- To investigate the association between RsaI and DraI polymorphisms of the CYP2E1 gene and the risk of sporadic prostate cancer.
Main Methods:
- A case-control study was conducted with 227 participants.
- Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to analyze RsaI and DraI polymorphisms in the CYP2E1 gene.
Main Results:
- The DD genotype of DraI polymorphisms was significantly over-represented in PCa cases compared to controls (OR 2.12, P=0.022).
- No significant association was found for RsaI polymorphisms of CYP2E1 with PCa risk.
Conclusions:
- DraI polymorphisms in the CYP2E1 gene may be associated with an increased risk of prostate cancer.
- The DD genotype of DraI might confer a twofold increased risk for PCa development.